Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy

European Urology

Volumn 62, Issue 4, 2012, Pages 649-655

  Avery, Kerry N L ^a   Metcalfe, Chris ^a   Vedhara, Kavita ^b   Lane, J Athene ^a   Davis, Michael ^a   Neal, David E ^c   Hamdy, Freddie C ^d   Donovan, Jenny L ^a   Blazeby, Jane M ^a,e  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Health behaviour; Mass screening; Prostatic neoplasms; Questionnaire

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; HEALTH BEHAVIOR; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUESTIONNAIRE;

AGED; COHORT STUDIES; DECISION MAKING; EARLY DETECTION OF CANCER; HEALTH BEHAVIOR; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 84865701480     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.12.059     Document Type: Article

References (29)

1. GLOBOCAN International Agency for Research on Cancer. Prostate cancer incidence and mortality worldwide in 2008. GLOBOCAN Web site. globocan.iarc.fr/factsheets/cancers/prostate.asp.
2. J. Lenzer, and S. Brownlee US expert panel recommends against prostate cancer screening BMJ 343 2011 d6479
3. G.L. Andriole, R.L. Grubb III, and S.S. Buys Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
4. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
5. R.M. Hoffman Screening for prostate cancer N Engl J Med 365 2011 2013 2019
6. R. Chou, J.M. Croswell, and T. Dana Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 155 2011 762 771
7. J.A. Lane, F.C. Hamdy, R.M. Martin, E.L. Turner, D.E. Neal, and J.L. Donovan Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies Eur J Cancer 46 2010 3095 3101
8. M. Conner, and P. Norman Predicting health behaviour: a social cognition approach M. Conner, P. Norman, Predicting health behaviour: research and practice with social cognition models, ed. 2 2005 Open University Press Maidenhead, UK 1 27
9. G. Berglund, S. Nilsson, and K. Nordin Intention to test for prostate cancer Eur J Cancer 41 2005 990 997
10. V. Champion Instrument development for health belief constructs ANS Adv Nurs Sci 6 1984 73 85
11. V. Champion Development of a benefits and barriers scale for mammography utilization Cancer Nurs 18 1995 53 59
12. B.C.H. Chiu, J.R. Anderson, and D. Corbin Predictors of prostate cancer screening among health fair participants Public Health 119 2005 686 693
13. M. Gattellari, J.M. Young, and J.E. Ward GP and patient predictors of PSA screening in Australian general practice Fam Pract 20 2003 294 303
14. C.B. Steele, D.S. Miller, C. Maylahn, R.J. Uhler, and C.T. Baker Knowledge, attitudes, and screening practices among older men regarding prostate cancer Am J Public Health 90 2000 1595 1600
15. P. Fayers, and D. Machin Quality of life: the assessment, analysis and interpretation of patient reported outcomes, ed. 2 2007 J. Wiley & Sons Chichester, UK
16. B.J. Tabachnik, and L.S. Fidel Using multivariate statistics 1993 Harper & Row London, UK
17. Office for National Statistics. Index of multiple deprivation deciles England, Wales, Scotland. 2011. Nomis Web site. https://www.nomisweb.co.uk/ articles/587.aspx.
18. K.N.L. Avery, J.M. Blazeby, J.A. Lane, D.E. Neal, F.C. Hamdy, and J.L. Donovan Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial Eur Urol 53 2008 1186 1193
19. H. Malmi, M. Ruutu, and L. Maatanen Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial BJU Int 106 2010 472 477
20. K.N.L. Avery, C. Metcalfe, and J.M. Blazeby Prostate -specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations? BJU Int 102 2008 1629 1633
21. H.J. Joseph Determinants of prostate cancer screening in a sample of African American military servicemen Mil Med 171 2006 430 435
22. M.L. Essink-Bot, H.J. de Koning, H.G. Nijs, W.J. Kirkels, P.J. van der Maas, and F.H. Schroder Short-term effects of population-based screening for prostate cancer on health-related quality of life J Natl Cancer Inst 90 1998 925 931
23. D. Rosario, J.A. Lane, and C. Metcalfe Short-term outcomes of prostate biopsy in men tested for cancer by PSA: a prospective evaluation within the ProtecT study BMJ 344 2012 d7894
24. C. Abraham, and P. Sheeran Understanding and changing health behaviour: from health beliefs to self-regulation P. Norman, C. Abraham, M. Conner, Understanding and changing health behaviour: from health beliefs to self-regulation, ed. 2 2000 Harwood Academic Publishers Amsterdam, Netherlands 3 24
25. S.C. Kalichman, M.P. Carey, and B.T. Johnson Prevention of sexually transmitted HIV infection: a meta-analytic review of the behavioral outcome literature Ann Behav Med 18 1996 6 15
26. C. Abraham, M.P. Kelly, R. West, and S. Michie The UK National Institute for Health and Clinical Excellence public health guidance on behaviour change: a brief introduction Psych Health Med 14 2009 1 8
27. P. Craig, P. Dieppe, and S. Macintyre Developing and evaluating complex interventions: new guidance 2008 Medical Research Council London, UK
28. K. Glanz, and B. Rimer National Cancer Institute. Theory at a glance: a guide for health promotion practice 2005 US Department of Health and Human Services Bethesda, MD
29. A. Ammerman, C. Lindquist, and J. Hersey Efficacy of interventions to modify dietary behavior related to cancer risk Evid Rep Technol Assess (Summ) 25 2000 1 4